Psychiatry Research最新文献

英文中文

Sex and youth mental health during the COVID-19 pandemic

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-13 DOI: 10.1016/j.psychres.2025.116403

Nathalie Auger , Gabriel Côté-Corriveau , Aimina Ayoub , Mimi Israël , Howard Steiger , Nicholas Chadi , Nancy Low

引用次数: 0

Maternal cannabis use disorder and offspring behavioral outcomes: findings from a linked data cohort study

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-13 DOI: 10.1016/j.psychres.2025.116404

Abay Woday Tadesse , Berihun Assefa Dachew , Getinet Ayano , Kim Betts , Rosa Alati

Few studies have explored the association between maternal gestational cannabis use and disruptive behavioural disorders (DBDs) in offspring, often relying on self-reported data and small samples. This study aimed to assess the relationship between maternal cannabis use disorder (CUD) during pregnancy and postpartum periods and the risk of disruptive behaviours in offspring. We conducted a population-based retrospective cohort study using linked health data from New South Wales, Australia, for live births between 2003 and 2005. Mothers with CUD were compared to those without, and the risk of DBDs in offspring was estimated. Both CUD and disruptive behavioural disorders were identified using the International Classification of Disease (ICD) codes. Generalised Linear Models (GLMs) with log-binomial regression were fitted to estimate disruptive behavioural disorder risk in children. Statistical significance was set at p < 0.05.

After adjusting for key confounders, this study revealed significantly higher risks of disruptive behavioural disorders in children of mothers with CUD during the antenatal [risk ratio (RR) = 3.56, 95 % CI 2.42–5.05], perinatal [RR = 3.55, 95 % CI 2.45–4.98], and postnatal [RR = 2.95, 95 % CI 1.23–6.16] periods compared to non-exposed counterparts. These findings underscore the importance of preconception, antenatal, and postnatal counselling on maternal cannabis use to mitigate neurobehavioral risks in children.

{"title":"Maternal cannabis use disorder and offspring behavioral outcomes: findings from a linked data cohort study","authors":"Abay Woday Tadesse , Berihun Assefa Dachew , Getinet Ayano , Kim Betts , Rosa Alati","doi":"10.1016/j.psychres.2025.116404","DOIUrl":"10.1016/j.psychres.2025.116404","url":null,"abstract":"<div><div>Few studies have explored the association between maternal gestational cannabis use and disruptive behavioural disorders (DBDs) in offspring, often relying on self-reported data and small samples. This study aimed to assess the relationship between maternal cannabis use disorder (CUD) during pregnancy and postpartum periods and the risk of disruptive behaviours in offspring. We conducted a population-based retrospective cohort study using linked health data from New South Wales, Australia, for live births between 2003 and 2005. Mothers with CUD were compared to those without, and the risk of DBDs in offspring was estimated. Both CUD and disruptive behavioural disorders were identified using the International Classification of Disease (ICD) codes. Generalised Linear Models (GLMs) with log-binomial regression were fitted to estimate disruptive behavioural disorder risk in children. Statistical significance was set at <em>p <</em> 0.05.</div><div>After adjusting for key confounders, this study revealed significantly higher risks of disruptive behavioural disorders in children of mothers with CUD during the antenatal [risk ratio (RR) = 3.56, 95 % CI 2.42–5.05], perinatal [RR = 3.55, 95 % CI 2.45–4.98], and postnatal [RR = 2.95, 95 % CI 1.23–6.16] periods compared to non-exposed counterparts. These findings underscore the importance of preconception, antenatal, and postnatal counselling on maternal cannabis use to mitigate neurobehavioral risks in children.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116404"},"PeriodicalIF":4.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of narcolepsy in representative samples of the general population of North America, Europe, and South Korea

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-13 DOI: 10.1016/j.psychres.2025.116390

Maurice M. Ohayon , Shreya Dave , Stephen Crawford , Todd J Swick , Marie-Lise Côté

Objectives

Narcolepsy is a rare, chronic, central disorder of hypersomnolence characterized by excessive daytime sleepiness, hypnagogic/hypnopompic hallucinations, sleep paralysis, disrupted nighttime sleep, and sometimes cataplexy (Type 1). The objective of this study was to assess the prevalence of narcolepsy in a large representative general population sample in North America, Europe, and Asia.

Methods

This cross-sectional epidemiological study utilized data from the Sleep-EVAL research database. The study involved 61,754 participants from 10 countries interviewed between 1992 and 2016 using the Sleep-EVAL Expert System, an artificial intelligence system designed to conduct interviews and perform positive and differential diagnoses based on interview responses. Using the answers provided for each symptom, the expert system built its diagnostic tree to reach a diagnostic conclusion of narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2) for each participant according to the International Classification of Sleep Disorders, Third Edition, criteria.

Results

Overall, the prevalence of NT1 was estimated to be 19.1/100,000 persons and the prevalence of NT2 was 23.3/100,000 persons. Prevalence of NT1 and NT2 was similar between countries and between men and women. Highest prevalence was among participants aged 35 years or younger for NT1 and among participants aged 35−54 years for NT2.

Conclusions

Our study, based on data from the general populations of several countries, shows that narcolepsy is a rare disorder, affecting 42.4/100,000 persons.

{"title":"Prevalence of narcolepsy in representative samples of the general population of North America, Europe, and South Korea","authors":"Maurice M. Ohayon , Shreya Dave , Stephen Crawford , Todd J Swick , Marie-Lise Côté","doi":"10.1016/j.psychres.2025.116390","DOIUrl":"10.1016/j.psychres.2025.116390","url":null,"abstract":"<div><h3>Objectives</h3><div>Narcolepsy is a rare, chronic, central disorder of hypersomnolence characterized by excessive daytime sleepiness, hypnagogic/hypnopompic hallucinations, sleep paralysis, disrupted nighttime sleep, and sometimes cataplexy (Type 1). The objective of this study was to assess the prevalence of narcolepsy in a large representative general population sample in North America, Europe, and Asia.</div></div><div><h3>Methods</h3><div>This cross-sectional epidemiological study utilized data from the Sleep-EVAL research database. The study involved 61,754 participants from 10 countries interviewed between 1992 and 2016 using the Sleep-EVAL Expert System, an artificial intelligence system designed to conduct interviews and perform positive and differential diagnoses based on interview responses. Using the answers provided for each symptom, the expert system built its diagnostic tree to reach a diagnostic conclusion of narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2) for each participant according to the <em>International Classification of Sleep Disorders</em>, Third Edition, criteria.</div></div><div><h3>Results</h3><div>Overall, the prevalence of NT1 was estimated to be 19.1/100,000 persons and the prevalence of NT2 was 23.3/100,000 persons. Prevalence of NT1 and NT2 was similar between countries and between men and women. Highest prevalence was among participants aged 35 years or younger for NT1 and among participants aged 35−54 years for NT2.</div></div><div><h3>Conclusions</h3><div>Our study, based on data from the general populations of several countries, shows that narcolepsy is a rare disorder, affecting 42.4/100,000 persons.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"347 ","pages":"Article 116390"},"PeriodicalIF":4.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suicide after psychedelic-assisted treatment in context

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-11 DOI: 10.1016/j.psychres.2025.116399

M. Earleywine , Zachary Herrmann , Sarah Slabaugh

引用次数: 0

Evaluation of alpha neurofeedback training to enhance sleep in remitted depression and anxiety sufferers with persistent insomnia

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-10 DOI: 10.1016/j.psychres.2025.116401

Tsung-Hua Lu , Tsung-Hao Hsieh , Yung-Hung Wang , Fu-Zen Shaw , Po See Chen , Sheng-Fu Liang

This study evaluates whether neurofeedback training (NFT) to boost alpha wave activity in the central brain may effectively mitigate persistent insomnia in patients with remitted depression and anxiety. Thirty-two participants in clinical remission from depression or anxiety were enrolled and evaluated for insomnia severity. Individuals were randomly assigned in a single-blinded manner to either NFT or the sham treatment. The effectiveness of the intervention was measured using recognized scales for depression, anxiety and sleep quality. While subjective sleep quality, measured by the PSQI, showed significant improvements in the active group compared to the sham group at post training, 1-month, 3-month, and 6-month follow-up, objective measures of sleep quality largely remained within the normal range, with few significant changes observed. Specifically, the active group exhibited notable improvements in alpha amplitude and duration during NFT sessions, which were not seen in the sham group. This highlights the potential of NFT as a complementary approach for improving sleep perception in this population, but further research is needed to confirm its effects on actual sleep architecture and long-term outcomes.

{"title":"Evaluation of alpha neurofeedback training to enhance sleep in remitted depression and anxiety sufferers with persistent insomnia","authors":"Tsung-Hua Lu , Tsung-Hao Hsieh , Yung-Hung Wang , Fu-Zen Shaw , Po See Chen , Sheng-Fu Liang","doi":"10.1016/j.psychres.2025.116401","DOIUrl":"10.1016/j.psychres.2025.116401","url":null,"abstract":"<div><div>This study evaluates whether neurofeedback training (NFT) to boost alpha wave activity in the central brain may effectively mitigate persistent insomnia in patients with remitted depression and anxiety. Thirty-two participants in clinical remission from depression or anxiety were enrolled and evaluated for insomnia severity. Individuals were randomly assigned in a single-blinded manner to either NFT or the sham treatment. The effectiveness of the intervention was measured using recognized scales for depression, anxiety and sleep quality. While subjective sleep quality, measured by the PSQI, showed significant improvements in the active group compared to the sham group at post training, 1-month, 3-month, and 6-month follow-up, objective measures of sleep quality largely remained within the normal range, with few significant changes observed. Specifically, the active group exhibited notable improvements in alpha amplitude and duration during NFT sessions, which were not seen in the sham group. This highlights the potential of NFT as a complementary approach for improving sleep perception in this population, but further research is needed to confirm its effects on actual sleep architecture and long-term outcomes.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116401"},"PeriodicalIF":4.2,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) – The PREVAIL study

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-10 DOI: 10.1016/j.psychres.2025.116387

Spyros Papapetropoulos , Elizabeth Doolin , Michael Odontiadis , Dharam Paul , Mark Jaros , Paul Rolan , Charles Taylor , Murray B. Stein

Social anxiety disorder (SAD) is a chronic, debilitating, and prevalent neuropsychiatric condition for which an acute, as-needed therapy is an unmet medical need. This Phase 2 study evaluated a potential novel, fast-acting, anxiolytic, BNC210, in SAD patients (NCT05193409). PREVAIL was a placebo-controlled, acute dose study of 225 mg and 675 mg BNC210 in 151 adult participants with SAD. Anxiety was evaluated by self-report efficacy scales during the anticipation and performance phases of a simulated public speaking challenge. Safety data were collected. Least squares mean ± standard error (SE) differences compared to placebo for the Subjective Units of Distress Scale (SUDS) scores for the change from baseline to the average of the performance phase were -6.6 ± 4.75 for 225 mg BNC210 and -4.8 ± 4.73 for 675 mg BNC210 (not significant). A post hoc analysis of SUDS scores evaluating combined BNC210 doses and speaking challenge phases (anticipation and performance) revealed a nominally statistically significant reduction compared to placebo (p = 0.044; effect size 0.36). Both dose levels of BNC210 demonstrated a favorable safety profile. PREVAIL supported further testing of 225 mg BNC210 as a potential safe and effective anxiolytic for acute, as-needed treatment of SAD. A Phase 3 trial is ongoing.

{"title":"A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) – The PREVAIL study","authors":"Spyros Papapetropoulos , Elizabeth Doolin , Michael Odontiadis , Dharam Paul , Mark Jaros , Paul Rolan , Charles Taylor , Murray B. Stein","doi":"10.1016/j.psychres.2025.116387","DOIUrl":"10.1016/j.psychres.2025.116387","url":null,"abstract":"<div><div>Social anxiety disorder (SAD) is a chronic, debilitating, and prevalent neuropsychiatric condition for which an acute, as-needed therapy is an unmet medical need. This Phase 2 study evaluated a potential novel, fast-acting, anxiolytic, BNC210, in SAD patients (NCT05193409). PREVAIL was a placebo-controlled, acute dose study of 225 mg and 675 mg BNC210 in 151 adult participants with SAD. Anxiety was evaluated by self-report efficacy scales during the anticipation and performance phases of a simulated public speaking challenge. Safety data were collected. Least squares mean ± standard error (SE) differences compared to placebo for the Subjective Units of Distress Scale (SUDS) scores for the change from baseline to the average of the performance phase were -6.6 ± 4.75 for 225 mg BNC210 and -4.8 ± 4.73 for 675 mg BNC210 (not significant). A <em>post hoc</em> analysis of SUDS scores evaluating combined BNC210 doses and speaking challenge phases (anticipation and performance) revealed a nominally statistically significant reduction compared to placebo (<em>p</em> = 0.044; effect size 0.36). Both dose levels of BNC210 demonstrated a favorable safety profile. PREVAIL supported further testing of 225 mg BNC210 as a potential safe and effective anxiolytic for acute, as-needed treatment of SAD. A Phase 3 trial is ongoing.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116387"},"PeriodicalIF":4.2,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Latent variable analysis of adherence to antipsychotics among south carolina medicaid beneficiaries with schizophrenia or schizoaffective disorder

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-10 DOI: 10.1016/j.psychres.2025.116402

Chao Cai , Pujing Zhao , Charmi Patel , Carmela Benson , Ismaeel Yunusa , Chris Kozma , Gene Reeder

Schizophrenia and schizoaffective disorder are chronic mental illnesses that may lead to positive symptoms, negative symptoms, or cognitive symptoms. This study examined latent classes within medication adherence profiles for long-acting injectable antipsychotics (LAIs) and oral antipsychotics (OAPs). Latent profile analysis (LPA) and multinomial logistic regression models were used to explore the association between patient characteristics and latent class membership. Four latent classes were identified using LPA with observed adherence measures. The classes were labeled as “best adherent”, “intermittent adherent”, “early drop-off”, and “worst adherent”, with their respective estimated prevalences of 58 %, 17 %, 9 %, and 16 %. Multinomial logistic regression showed that patients on LAIs were more likely to belong to the “best adherent” group than to the non-adherent groups (“intermittent adherent”, “early drop-off”, and “worst adherent”) when compared to those on OAPs. These findings may contribute to the development of strategies for medication prescription and disease management for people with schizophrenia or schizoaffective disorder.

{"title":"Latent variable analysis of adherence to antipsychotics among south carolina medicaid beneficiaries with schizophrenia or schizoaffective disorder","authors":"Chao Cai , Pujing Zhao , Charmi Patel , Carmela Benson , Ismaeel Yunusa , Chris Kozma , Gene Reeder","doi":"10.1016/j.psychres.2025.116402","DOIUrl":"10.1016/j.psychres.2025.116402","url":null,"abstract":"<div><div>Schizophrenia and schizoaffective disorder are chronic mental illnesses that may lead to positive symptoms, negative symptoms, or cognitive symptoms. This study examined latent classes within medication adherence profiles for long-acting injectable antipsychotics (LAIs) and oral antipsychotics (OAPs). Latent profile analysis (LPA) and multinomial logistic regression models were used to explore the association between patient characteristics and latent class membership. Four latent classes were identified using LPA with observed adherence measures. The classes were labeled as “best adherent”, “intermittent adherent”, “early drop-off”, and “worst adherent”, with their respective estimated prevalences of 58 %, 17 %, 9 %, and 16 %. Multinomial logistic regression showed that patients on LAIs were more likely to belong to the “best adherent” group than to the non-adherent groups (“intermittent adherent”, “early drop-off”, and “worst adherent”) when compared to those on OAPs. These findings may contribute to the development of strategies for medication prescription and disease management for people with schizophrenia or schizoaffective disorder.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116402"},"PeriodicalIF":4.2,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143445849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gut microbiota causes depressive phenotype by modulating glycerophospholipid and sphingolipid metabolism via the gut-brain axis

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-07 DOI: 10.1016/j.psychres.2025.116392

Yanan Cao , Xiaoxiao Fan , Tianzi Zang , Yanting Li , Yiming Tu , Yi Wei , Jinbing Bai , Yanqun Liu

Emerging evidence suggests that changes in the gut microbiota (GM) are related to prenatal depression onset, but the underlying molecular mechanisms remain obscure. This study was conducted to explore how disordered GM is involved in the onset of prenatal depression through the microbiome-gut-brain (MGB) axis. We transplanted fecal microbiota from women with and without prenatal depression into germ-free mice. Fecal metagenomic sequencing and LC-MS untargeted metabolomics analysis were performed to identify the GM composition, function, and metabolites in mice. Lipid metabolomics analysis was then used to characterize the lipid metabolism of brain tissue in mice. We found that mice transplanted with fecal microbiota from women with prenatal depression exhibited depressive-like behaviors as well as characteristic disorders of the phylum Firmicutes. Weighted Gene Correlation Network Analysis identified three microbial and one metabolic module in the gut, alongside two lipid metabolic modules in the brain, as significantly related to all depressive-like behaviors. These modules were enriched for glycerophospholipid and sphingolipid metabolism. In addition, the GM of mice with depressive-like behaviors were enriched and deficient in relevant functions and enzymes in the glycerophospholipid (mainly phosphatidylethanolamine) and sphingolipid (mainly hexosyl-ceramide) metabolic pathways, respectively. Consistently, glycerophospholipid and sphingolipid metabolites in the brains of depressive-like mice were up- and down-regulated. Increased phosphatidylethanolamine and decreased hexosyl-ceramide were significantly related to differential genera in the gut. Collectively, our findings provide a novel microbial and metabolic framework for understanding the role of the MGB axis in prenatal depression, indicating that the GM may be involved in the onset of depressive phenotypes by modulating central glycerophospholipid and sphingolipid metabolic homeostasis.

{"title":"Gut microbiota causes depressive phenotype by modulating glycerophospholipid and sphingolipid metabolism via the gut-brain axis","authors":"Yanan Cao , Xiaoxiao Fan , Tianzi Zang , Yanting Li , Yiming Tu , Yi Wei , Jinbing Bai , Yanqun Liu","doi":"10.1016/j.psychres.2025.116392","DOIUrl":"10.1016/j.psychres.2025.116392","url":null,"abstract":"<div><div>Emerging evidence suggests that changes in the gut microbiota (GM) are related to prenatal depression onset, but the underlying molecular mechanisms remain obscure. This study was conducted to explore how disordered GM is involved in the onset of prenatal depression through the microbiome-gut-brain (MGB) axis. We transplanted fecal microbiota from women with and without prenatal depression into germ-free mice. Fecal metagenomic sequencing and LC-MS untargeted metabolomics analysis were performed to identify the GM composition, function, and metabolites in mice. Lipid metabolomics analysis was then used to characterize the lipid metabolism of brain tissue in mice. We found that mice transplanted with fecal microbiota from women with prenatal depression exhibited depressive-like behaviors as well as characteristic disorders of the phylum <em>Firmicutes</em>. Weighted Gene Correlation Network Analysis identified three microbial and one metabolic module in the gut, alongside two lipid metabolic modules in the brain, as significantly related to all depressive-like behaviors. These modules were enriched for glycerophospholipid and sphingolipid metabolism. In addition, the GM of mice with depressive-like behaviors were enriched and deficient in relevant functions and enzymes in the glycerophospholipid (mainly phosphatidylethanolamine) and sphingolipid (mainly hexosyl-ceramide) metabolic pathways, respectively. Consistently, glycerophospholipid and sphingolipid metabolites in the brains of depressive-like mice were up- and down-regulated. Increased phosphatidylethanolamine and decreased hexosyl-ceramide were significantly related to differential genera in the gut. Collectively, our findings provide a novel microbial and metabolic framework for understanding the role of the MGB axis in prenatal depression, indicating that the GM may be involved in the onset of depressive phenotypes by modulating central glycerophospholipid and sphingolipid metabolic homeostasis.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116392"},"PeriodicalIF":4.2,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recreational Marijuana Laws and suicide deaths in the US

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-04 DOI: 10.1016/j.psychres.2025.116386

Nawar Nayeem , Erick Messias , Ping-I Lin

Objectives

This study aimed to examine the association between Recreational Marijuana Laws (RMLs) and age-adjusted suicide rates in the U.S. population from 2000 to 2022.

Methods

Suicide rate data were obtained from the Centers for Disease Control and Prevention's (CDC) Multiple Cause of Death Files at the state and year level. Information on RML status and years of legalization was sourced from the National Organization for the Reform of Marijuana Laws (NORML). Using a staggered difference-in-differences (DiD) framework, we assessed the relationship between RMLs and age-adjusted suicide rates.

Results

RMLs were associated with an increase of 0.68 suicide deaths per 100,000 population (p-value < 0.05). This increase was primarily driven by states that implemented RMLs in 2018 (Maine, Vermont, and Michigan) and 2019 (Illinois). In contrast, states that enacted RMLs in 2015 (Alaska, Oregon, and Washington, D.C.) experienced a decline in suicide deaths post-legalization.

Conclusion

This study adds to the growing body of literature on RMLs and suicidality by underscoring the potential role of state-specific factors—such as demographic characteristics, implementation strategies, or contextual differences—in shaping the direction and magnitude of this association. These findings highlight the need for further research to better understand the mechanisms underlying these divergent outcomes.

{"title":"Recreational Marijuana Laws and suicide deaths in the US","authors":"Nawar Nayeem , Erick Messias , Ping-I Lin","doi":"10.1016/j.psychres.2025.116386","DOIUrl":"10.1016/j.psychres.2025.116386","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to examine the association between Recreational Marijuana Laws (RMLs) and age-adjusted suicide rates in the U.S. population from 2000 to 2022.</div></div><div><h3>Methods</h3><div>Suicide rate data were obtained from the Centers for Disease Control and Prevention's (CDC) Multiple Cause of Death Files at the state and year level. Information on RML status and years of legalization was sourced from the National Organization for the Reform of Marijuana Laws (NORML). Using a staggered difference-in-differences (DiD) framework, we assessed the relationship between RMLs and age-adjusted suicide rates.</div></div><div><h3>Results</h3><div>RMLs were associated with an increase of 0.68 suicide deaths per 100,000 population (p-value < 0.05). This increase was primarily driven by states that implemented RMLs in 2018 (Maine, Vermont, and Michigan) and 2019 (Illinois). In contrast, states that enacted RMLs in 2015 (Alaska, Oregon, and Washington, D.C.) experienced a decline in suicide deaths post-legalization.</div></div><div><h3>Conclusion</h3><div>This study adds to the growing body of literature on RMLs and suicidality by underscoring the potential role of state-specific factors—such as demographic characteristics, implementation strategies, or contextual differences—in shaping the direction and magnitude of this association. These findings highlight the need for further research to better understand the mechanisms underlying these divergent outcomes.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"345 ","pages":"Article 116386"},"PeriodicalIF":4.2,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting the relationship between impaired social functioning and psychopathology in schizophrenia

IF 4.2 2区医学 Q1 PSYCHIATRY

Psychiatry Research

Pub Date : 2025-02-04 DOI: 10.1016/j.psychres.2025.116389

Rasmus Handest , Ida-Marie Mølstrøm , Mads Gram Henriksen , Julie Nordgaard

Impaired social functioning is a common and well-known feature of schizophrenia. The relationship between psychopathology and social functioning is poorly understood, but substance use disorder is often suspected to negatively impact social functioning.

In this empirical study, we explored the relationship between psychopathology and social functioning in two groups of patients with schizophrenia spectrum disorders with impaired social functioning: homeless and domiciled patients. The patients were thoroughly examined for psychopathology, social functioning, and substance use disorder.

The results showed that all domains of psychopathology correlated significantly and negatively with social functioning. The homeless group was worse off than the domiciled group on social functioning scales, but this difference was not reflected in differences in psychopathology or substance use disorder among the two groups. Moreover, the homeless group had more disturbed and aggressive behavior, less contact with relatives, and experienced more childhood trauma and imprisonment compared with the domiciled patients.

Our findings seemingly challenge the prevailing explanatory models of impaired social functioning in schizophrenia as being a result of negative symptoms or substance use disorder. Finally, the intertwinement of psychopathology and social functioning in assessment measures should be considered before concluding how specific psychopathological domains affect social functioning in schizophrenia.

{"title":"Revisiting the relationship between impaired social functioning and psychopathology in schizophrenia","authors":"Rasmus Handest , Ida-Marie Mølstrøm , Mads Gram Henriksen , Julie Nordgaard","doi":"10.1016/j.psychres.2025.116389","DOIUrl":"10.1016/j.psychres.2025.116389","url":null,"abstract":"<div><div>Impaired social functioning is a common and well-known feature of schizophrenia. The relationship between psychopathology and social functioning is poorly understood, but substance use disorder is often suspected to negatively impact social functioning.</div><div>In this empirical study, we explored the relationship between psychopathology and social functioning in two groups of patients with schizophrenia spectrum disorders with impaired social functioning: homeless and domiciled patients. The patients were thoroughly examined for psychopathology, social functioning, and substance use disorder.</div><div>The results showed that all domains of psychopathology correlated significantly and negatively with social functioning. The homeless group was worse off than the domiciled group on social functioning scales, but this difference was not reflected in differences in psychopathology or substance use disorder among the two groups. Moreover, the homeless group had more disturbed and aggressive behavior, less contact with relatives, and experienced more childhood trauma and imprisonment compared with the domiciled patients.</div><div>Our findings seemingly challenge the prevailing explanatory models of impaired social functioning in schizophrenia as being a result of negative symptoms or substance use disorder. Finally, the intertwinement of psychopathology and social functioning in assessment measures should be considered before concluding how specific psychopathological domains affect social functioning in schizophrenia.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"346 ","pages":"Article 116389"},"PeriodicalIF":4.2,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Psychiatry Research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀